Your browser doesn't support javascript.
loading
Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP).
Butzkueven, Helmut; Trojano, Maria; Kappos, Ludwig; Spelman, Tim; Wiendl, Heinz; Rosales, Karen; Su, Ray; Licata, Stephanie; Ho, Pei-Ran; Campbell, Nolan.
Afiliação
  • Butzkueven H; Department of Neuroscience, Central Clinical School, Alfred Campus, Monash University, Melbourne, VIC, Australia/Department of Neurology, Box Hill Hospital, Monash University, Box Hill, VIC, Australia.
  • Trojano M; Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy.
  • Kappos L; Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital, University of Basel, Basel, Switzerland.
  • Spelman T; Department of Medicine and Melbourne Brain Centre, Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC, Australia.
  • Wiendl H; Department of Neurology-Inflammatory Disorders of the Nervous System and Neuro-Oncology, University of Münster, Münster, Germany.
  • Rosales K; Biogen, Cambridge, MA, USA.
  • Su R; Biogen, Cambridge, MA, USA.
  • Licata S; Biogen, Cambridge, MA, USA.
  • Ho PR; Biogen, Cambridge, MA, USA.
  • Campbell N; Biogen, Cambridge, MA, USA.
Mult Scler ; 27(3): 410-419, 2021 03.
Article em En | MEDLINE | ID: mdl-32406786
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Fatores Imunológicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Fatores Imunológicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article